- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CENTURY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.08. | Century Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.08. | Century Therapeutics GAAP EPS of -$0.38 | 2 | Seeking Alpha | ||
| 14.08. | Century Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.08. | Century Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | Century Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | 201 | GlobeNewswire (Europe) | Patient dosing ongoing in CALiPSO-1 trial; on track to report clinical data for CNTY-101 in patients with B-cell-mediated autoimmune diseases by year-end 2025CNTY-308, a CAR-iT cell therapy functionally... ► Artikel lesen | |
| 10.07. | Century Therapeutics files $200M mixed shelf offering | 4 | Seeking Alpha | ||
| 07.07. | Century Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.06. | Century Therapeutics hält jährliche Aktionärsversammlung ab | 15 | Investing.com Deutsch | ||
| 16.06. | Century Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 28.05. | Century Therapeutics, Inc.: Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress | 13 | GlobeNewswire (USA) | ||
| 16.05. | Century Therapeutics GAAP EPS of $0.89, revenue of $109.16M | 2 | Seeking Alpha | ||
| 15.05. | Century Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | 316 | GlobeNewswire (Europe) | Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and... ► Artikel lesen | |
| 19.03. | Century Therapeutics, Inc.: Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 190 | GlobeNewswire (Europe) | Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell mediated autoimmune diseases and malignancies New concentrated... ► Artikel lesen | |
| 21.01. | Century Therapeutics, Inc.: Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned ... | 185 | GlobeNewswire (Europe) | - Investigator-initiated trial (IIT) to be led by pioneers of cell therapy in B-cell mediated autoimmune disease, the Schett/Mackensen group at Friedrich-Alexander University Erlangen-Nürnberg - -... ► Artikel lesen | |
| 05.11.24 | Century Therapeutics, Inc.: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates | 216 | GlobeNewswire (Europe) | - Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy -- Overall response rate (ORR) of 83%... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,054 | -0,59 % | EQS-News: Evotec SE: Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec gibt Fortschritt in präklinischer Neurologie-Partnerschaft mit Bristol Myers Squibb bekannt
27.10.2025 / 07:30 CET/CEST
Für... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,520 | +1,53 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| ABIVAX | 90,20 | +0,67 % | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| GERON | 1,109 | +1,93 % | Geron Corporation Announces Executive Leadership Transitions and Appointments | FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,390 | +2,57 % | FDA-Sonderstatus für Krebstherapie beflügelt Cellectar-Aktie | ||
| GALAPAGOS NV | 27,140 | -1,52 % | Galapagos NV: Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development | New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board
Mechelen, Belgium; October 30, 2025, 21:01 CET - Galapagos NV (Euronext & NASDAQ:... ► Artikel lesen | |
| VIDAC PHARMA | 0,530 | +3,52 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CYTOKINETICS | 55,00 | -0,90 % | Cytokinetics, Incorporated: Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025 | ||
| CYTOMX THERAPEUTICS | 3,110 | +0,26 % | CytomX Therapeutics Inc.: CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 | ||
| PALISADE BIO | 2,060 | +5,64 % | Palisade Bio, Inc.: Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations | Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on... ► Artikel lesen | |
| FIBROGEN | 9,300 | 0,00 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,050 | -3,07 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| PERSONALIS | 8,205 | -1,56 % | Personalis, Inc.: Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing | Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (LAURA). The findings demonstrate... ► Artikel lesen |
Das Unternehmen CENTURY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,77 % bei einem Aktienkurs von 0,582 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CENTURY THERAPEUTICS INC finden Sie auf Wallstreet Online.